As of 2026-04-03, the EV/EBITDA ratio of Redhill Biopharma Ltd (RDHL) is -0.13. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RDHL's latest enterprise value is 2.17 mil USD. RDHL's TTM EBITDA according to its financial statements is -16.23 mil USD. Dividing these 2 quantities gives us the above RDHL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.4x - 12.1x | 8.0x |
| Forward P/E multiples | 6.1x - 9.6x | 8.0x |
| Fair Price | (15.99) - (25.46) | (21.10) |
| Upside | -2099.8% - -3285.5% | -2739.8% |
| Date | EV/EBITDA |
| 2026-04-02 | -0.13 |
| 2026-04-01 | -0.14 |
| 2026-03-31 | -0.11 |
| 2026-03-30 | -0.11 |
| 2026-03-27 | -0.12 |
| 2026-03-26 | -0.13 |
| 2026-03-25 | -0.17 |
| 2026-03-24 | -0.17 |
| 2026-03-23 | -0.16 |
| 2026-03-20 | -0.16 |
| 2026-03-19 | -0.17 |
| 2026-03-18 | -0.15 |
| 2026-03-17 | -0.16 |
| 2026-03-16 | -0.15 |
| 2026-03-13 | -0.16 |
| 2026-03-12 | -0.16 |
| 2026-03-11 | -0.16 |
| 2026-03-10 | -0.17 |
| 2026-03-09 | -0.18 |
| 2026-03-06 | -0.18 |
| 2026-03-05 | -0.19 |
| 2026-03-04 | -0.19 |
| 2026-03-03 | -0.19 |
| 2026-03-02 | -0.18 |
| 2026-02-27 | -0.20 |
| 2026-02-26 | -0.20 |
| 2026-02-25 | -0.19 |
| 2026-02-24 | -0.20 |
| 2026-02-23 | -0.19 |
| 2026-02-20 | -0.20 |
| 2026-02-19 | -0.22 |
| 2026-02-18 | -0.21 |
| 2026-02-17 | -0.22 |
| 2026-02-13 | -0.21 |
| 2026-02-12 | -0.20 |
| 2026-02-11 | -0.19 |
| 2026-02-10 | -0.21 |
| 2026-02-09 | -0.23 |
| 2026-02-06 | -0.23 |
| 2026-02-05 | -0.22 |
| 2026-02-04 | -0.23 |
| 2026-02-03 | -0.25 |
| 2026-02-02 | -0.26 |
| 2026-01-30 | -0.29 |
| 2026-01-29 | -0.31 |
| 2026-01-28 | -0.32 |
| 2026-01-27 | -0.33 |
| 2026-01-26 | -0.32 |
| 2026-01-23 | -0.34 |
| 2026-01-22 | -0.33 |